SLC5A2 and type 2 diabetes mellitus: GLP‐1 receptor agonists, PPAR‐γ‐agonists, SGLT2‐inhibitors and perhaps the newer GIP/GLP‐1 receptor agonists may all be preferred pharmacological interventions for patients with MASLD and T2DM.